Acceptability of Intanza® 15 μg intradermal influenza vaccine in Belgium during the 2010-2011 influenza season.
Identifieur interne : 000056 ( Main/Exploration ); précédent : 000055; suivant : 000057Acceptability of Intanza® 15 μg intradermal influenza vaccine in Belgium during the 2010-2011 influenza season.
Auteurs : Patrick A. Dhont [Belgique] ; Adelin Albert ; Patrick Brenders ; Anna Podwapinska ; Ann Pollet ; Dirk Scheveneels ; François Tihon ; Ilse Verheyden ; Jan Victor ; Sandrine I. SamsonSource :
- Advances in therapy [ 1865-8652 ] ; 2012.
Descripteurs français
- KwdFr :
- Acceptation des soins par le patient, Adulte d'âge moyen, Belgique, Femelle, Humains, Injections intradermiques, Mâle, Médecins généralistes, Satisfaction du patient, Sujet âgé, Sujet âgé de 80 ans ou plus, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (usage thérapeutique), Vaccins inactivés, Études prospectives.
- MESH :
- administration et posologie : Vaccins antigrippaux.
- usage thérapeutique : Vaccins antigrippaux.
- Acceptation des soins par le patient, Adulte d'âge moyen, Belgique, Femelle, Humains, Injections intradermiques, Mâle, Médecins généralistes, Satisfaction du patient, Sujet âgé, Sujet âgé de 80 ans ou plus, Vaccins inactivés, Études prospectives.
- Wicri :
- geographic : Belgique.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Belgium, Female, General Practitioners, Humans, Influenza Vaccines (administration & dosage), Influenza Vaccines (therapeutic use), Injections, Intradermal, Male, Middle Aged, Patient Acceptance of Health Care, Patient Satisfaction, Prospective Studies, Vaccines, Inactivated.
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , therapeutic use : Influenza Vaccines.
- geographic : Belgium, Vaccines, Inactivated.
- Aged, Aged, 80 and over, Female, General Practitioners, Humans, Injections, Intradermal, Male, Middle Aged, Patient Acceptance of Health Care, Patient Satisfaction, Prospective Studies.
Abstract
INTRODUCTION
Intradermal (ID) influenza vaccination induces an enhanced immune response in the elderly when compared with intramuscular (IM) vaccination. In 2009, an ID seasonal influenza vaccine (Intanza(®) [Sanofi Pasteur MSD, Lyon, France] 15 μg) was approved for use in individuals aged ≥ 60 years in Europe. This survey conducted in Belgium was the first in Europe to assess the acceptability of this vaccine in routine clinical practice by vaccinees and their general practitioners (GPs).
METHODS
GPs willing to use both the ID and IM influenza vaccines were selected during the 2010-2011 influenza season. Each GP recruited ≤ 10 patients aged ≥ 60 years who received the ID vaccine. Vaccinees and GPs completed questionnaires about their opinions on influenza vaccination and the acceptability of the ID influenza vaccine.
RESULTS
In total, 105 GPs and 837 vaccinees completed questionnaires. A high proportion of vaccinees (40.3%) was aged ≥ 75 years, and 95.5% had been vaccinated the previous year. The majority of vaccinees was very satisfied (70.0%) or satisfied (27.9%) with the ID vaccine. The main reasons for the high satisfaction rate were that the injection was not very painful, administration was quick, and the vaccinee felt confident about the micro-needle injection system. Most vaccinees (91.1%) who had previously received IM influenza vaccination preferred the ID vaccine, and 98.5% of vaccinees reported they would consider receiving the ID vaccine the following year. The majority of GPs was very satisfied (78.6%) or satisfied (18.4%) with the ID vaccine, and most GPs (87.6%) expressed a preference for the ID vaccine over IM influenza vaccine.
CONCLUSION
The ID influenza vaccine was well accepted by vaccinees and their GPs, who expressed a preference for the ID vaccine over conventional IM influenza vaccine. The availability of the ID influenza vaccine may help to improve uptake of seasonal influenza vaccination in the elderly.
DOI: 10.1007/s12325-012-0025-9
PubMed: 22678831
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Acceptability of Intanza® 15 μg intradermal influenza vaccine in Belgium during the 2010-2011 influenza season.</title><author><name sortKey="Dhont, Patrick A" sort="Dhont, Patrick A" uniqKey="Dhont P" first="Patrick A" last="Dhont">Patrick A. Dhont</name><affiliation wicri:level="3"><nlm:affiliation>Sanofi Pasteur MSD, Brussels, Belgium. pdhont@spmsd.com</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Sanofi Pasteur MSD, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Albert, Adelin" sort="Albert, Adelin" uniqKey="Albert A" first="Adelin" last="Albert">Adelin Albert</name></author><author><name sortKey="Brenders, Patrick" sort="Brenders, Patrick" uniqKey="Brenders P" first="Patrick" last="Brenders">Patrick Brenders</name></author><author><name sortKey="Podwapinska, Anna" sort="Podwapinska, Anna" uniqKey="Podwapinska A" first="Anna" last="Podwapinska">Anna Podwapinska</name></author><author><name sortKey="Pollet, Ann" sort="Pollet, Ann" uniqKey="Pollet A" first="Ann" last="Pollet">Ann Pollet</name></author><author><name sortKey="Scheveneels, Dirk" sort="Scheveneels, Dirk" uniqKey="Scheveneels D" first="Dirk" last="Scheveneels">Dirk Scheveneels</name></author><author><name sortKey="Tihon, Francois" sort="Tihon, Francois" uniqKey="Tihon F" first="François" last="Tihon">François Tihon</name></author><author><name sortKey="Verheyden, Ilse" sort="Verheyden, Ilse" uniqKey="Verheyden I" first="Ilse" last="Verheyden">Ilse Verheyden</name></author><author><name sortKey="Victor, Jan" sort="Victor, Jan" uniqKey="Victor J" first="Jan" last="Victor">Jan Victor</name></author><author><name sortKey="Samson, Sandrine I" sort="Samson, Sandrine I" uniqKey="Samson S" first="Sandrine I" last="Samson">Sandrine I. Samson</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22678831</idno><idno type="pmid">22678831</idno><idno type="doi">10.1007/s12325-012-0025-9</idno><idno type="wicri:Area/Main/Corpus">000055</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000055</idno><idno type="wicri:Area/Main/Curation">000055</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000055</idno><idno type="wicri:Area/Main/Exploration">000055</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Acceptability of Intanza® 15 μg intradermal influenza vaccine in Belgium during the 2010-2011 influenza season.</title><author><name sortKey="Dhont, Patrick A" sort="Dhont, Patrick A" uniqKey="Dhont P" first="Patrick A" last="Dhont">Patrick A. Dhont</name><affiliation wicri:level="3"><nlm:affiliation>Sanofi Pasteur MSD, Brussels, Belgium. pdhont@spmsd.com</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Sanofi Pasteur MSD, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Albert, Adelin" sort="Albert, Adelin" uniqKey="Albert A" first="Adelin" last="Albert">Adelin Albert</name></author><author><name sortKey="Brenders, Patrick" sort="Brenders, Patrick" uniqKey="Brenders P" first="Patrick" last="Brenders">Patrick Brenders</name></author><author><name sortKey="Podwapinska, Anna" sort="Podwapinska, Anna" uniqKey="Podwapinska A" first="Anna" last="Podwapinska">Anna Podwapinska</name></author><author><name sortKey="Pollet, Ann" sort="Pollet, Ann" uniqKey="Pollet A" first="Ann" last="Pollet">Ann Pollet</name></author><author><name sortKey="Scheveneels, Dirk" sort="Scheveneels, Dirk" uniqKey="Scheveneels D" first="Dirk" last="Scheveneels">Dirk Scheveneels</name></author><author><name sortKey="Tihon, Francois" sort="Tihon, Francois" uniqKey="Tihon F" first="François" last="Tihon">François Tihon</name></author><author><name sortKey="Verheyden, Ilse" sort="Verheyden, Ilse" uniqKey="Verheyden I" first="Ilse" last="Verheyden">Ilse Verheyden</name></author><author><name sortKey="Victor, Jan" sort="Victor, Jan" uniqKey="Victor J" first="Jan" last="Victor">Jan Victor</name></author><author><name sortKey="Samson, Sandrine I" sort="Samson, Sandrine I" uniqKey="Samson S" first="Sandrine I" last="Samson">Sandrine I. Samson</name></author></analytic><series><title level="j">Advances in therapy</title><idno type="eISSN">1865-8652</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Belgium</term><term>Female</term><term>General Practitioners</term><term>Humans</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (therapeutic use)</term><term>Injections, Intradermal</term><term>Male</term><term>Middle Aged</term><term>Patient Acceptance of Health Care</term><term>Patient Satisfaction</term><term>Prospective Studies</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acceptation des soins par le patient</term><term>Adulte d'âge moyen</term><term>Belgique</term><term>Femelle</term><term>Humains</term><term>Injections intradermiques</term><term>Mâle</term><term>Médecins généralistes</term><term>Satisfaction du patient</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (usage thérapeutique)</term><term>Vaccins inactivés</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Belgium</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>General Practitioners</term><term>Humans</term><term>Injections, Intradermal</term><term>Male</term><term>Middle Aged</term><term>Patient Acceptance of Health Care</term><term>Patient Satisfaction</term><term>Prospective Studies</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Acceptation des soins par le patient</term><term>Adulte d'âge moyen</term><term>Belgique</term><term>Femelle</term><term>Humains</term><term>Injections intradermiques</term><term>Mâle</term><term>Médecins généralistes</term><term>Satisfaction du patient</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Vaccins inactivés</term><term>Études prospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Belgique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b></p><p>Intradermal (ID) influenza vaccination induces an enhanced immune response in the elderly when compared with intramuscular (IM) vaccination. In 2009, an ID seasonal influenza vaccine (Intanza(®) [Sanofi Pasteur MSD, Lyon, France] 15 μg) was approved for use in individuals aged ≥ 60 years in Europe. This survey conducted in Belgium was the first in Europe to assess the acceptability of this vaccine in routine clinical practice by vaccinees and their general practitioners (GPs).</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>GPs willing to use both the ID and IM influenza vaccines were selected during the 2010-2011 influenza season. Each GP recruited ≤ 10 patients aged ≥ 60 years who received the ID vaccine. Vaccinees and GPs completed questionnaires about their opinions on influenza vaccination and the acceptability of the ID influenza vaccine.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>In total, 105 GPs and 837 vaccinees completed questionnaires. A high proportion of vaccinees (40.3%) was aged ≥ 75 years, and 95.5% had been vaccinated the previous year. The majority of vaccinees was very satisfied (70.0%) or satisfied (27.9%) with the ID vaccine. The main reasons for the high satisfaction rate were that the injection was not very painful, administration was quick, and the vaccinee felt confident about the micro-needle injection system. Most vaccinees (91.1%) who had previously received IM influenza vaccination preferred the ID vaccine, and 98.5% of vaccinees reported they would consider receiving the ID vaccine the following year. The majority of GPs was very satisfied (78.6%) or satisfied (18.4%) with the ID vaccine, and most GPs (87.6%) expressed a preference for the ID vaccine over IM influenza vaccine.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>The ID influenza vaccine was well accepted by vaccinees and their GPs, who expressed a preference for the ID vaccine over conventional IM influenza vaccine. The availability of the ID influenza vaccine may help to improve uptake of seasonal influenza vaccination in the elderly.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22678831</PMID><DateCompleted><Year>2012</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2012</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-8652</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Advances in therapy</Title><ISOAbbreviation>Adv Ther</ISOAbbreviation></Journal><ArticleTitle>Acceptability of Intanza® 15 μg intradermal influenza vaccine in Belgium during the 2010-2011 influenza season.</ArticleTitle><Pagination><MedlinePgn>562-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12325-012-0025-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Intradermal (ID) influenza vaccination induces an enhanced immune response in the elderly when compared with intramuscular (IM) vaccination. In 2009, an ID seasonal influenza vaccine (Intanza(®) [Sanofi Pasteur MSD, Lyon, France] 15 μg) was approved for use in individuals aged ≥ 60 years in Europe. This survey conducted in Belgium was the first in Europe to assess the acceptability of this vaccine in routine clinical practice by vaccinees and their general practitioners (GPs).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">GPs willing to use both the ID and IM influenza vaccines were selected during the 2010-2011 influenza season. Each GP recruited ≤ 10 patients aged ≥ 60 years who received the ID vaccine. Vaccinees and GPs completed questionnaires about their opinions on influenza vaccination and the acceptability of the ID influenza vaccine.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 105 GPs and 837 vaccinees completed questionnaires. A high proportion of vaccinees (40.3%) was aged ≥ 75 years, and 95.5% had been vaccinated the previous year. The majority of vaccinees was very satisfied (70.0%) or satisfied (27.9%) with the ID vaccine. The main reasons for the high satisfaction rate were that the injection was not very painful, administration was quick, and the vaccinee felt confident about the micro-needle injection system. Most vaccinees (91.1%) who had previously received IM influenza vaccination preferred the ID vaccine, and 98.5% of vaccinees reported they would consider receiving the ID vaccine the following year. The majority of GPs was very satisfied (78.6%) or satisfied (18.4%) with the ID vaccine, and most GPs (87.6%) expressed a preference for the ID vaccine over IM influenza vaccine.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The ID influenza vaccine was well accepted by vaccinees and their GPs, who expressed a preference for the ID vaccine over conventional IM influenza vaccine. The availability of the ID influenza vaccine may help to improve uptake of seasonal influenza vaccination in the elderly.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dhont</LastName><ForeName>Patrick A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Sanofi Pasteur MSD, Brussels, Belgium. pdhont@spmsd.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Adelin</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Brenders</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Podwapinska</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pollet</LastName><ForeName>Ann</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Scheveneels</LastName><ForeName>Dirk</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Tihon</LastName><ForeName>François</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Verheyden</LastName><ForeName>Ilse</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Victor</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Samson</LastName><ForeName>Sandrine I</ForeName><Initials>SI</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Ther</MedlineTA><NlmUniqueID>8611864</NlmUniqueID><ISSNLinking>0741-238X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>T</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N" Type="Geographic">Belgium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058005" MajorTopicYN="Y">General Practitioners</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007271" MajorTopicYN="N">Injections, Intradermal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="Y">Patient Acceptance of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>03</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22678831</ArticleId><ArticleId IdType="doi">10.1007/s12325-012-0025-9</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Belgique</li></country><region><li>Région de Bruxelles-Capitale</li></region><settlement><li>Bruxelles</li></settlement></list><tree><noCountry><name sortKey="Albert, Adelin" sort="Albert, Adelin" uniqKey="Albert A" first="Adelin" last="Albert">Adelin Albert</name><name sortKey="Brenders, Patrick" sort="Brenders, Patrick" uniqKey="Brenders P" first="Patrick" last="Brenders">Patrick Brenders</name><name sortKey="Podwapinska, Anna" sort="Podwapinska, Anna" uniqKey="Podwapinska A" first="Anna" last="Podwapinska">Anna Podwapinska</name><name sortKey="Pollet, Ann" sort="Pollet, Ann" uniqKey="Pollet A" first="Ann" last="Pollet">Ann Pollet</name><name sortKey="Samson, Sandrine I" sort="Samson, Sandrine I" uniqKey="Samson S" first="Sandrine I" last="Samson">Sandrine I. Samson</name><name sortKey="Scheveneels, Dirk" sort="Scheveneels, Dirk" uniqKey="Scheveneels D" first="Dirk" last="Scheveneels">Dirk Scheveneels</name><name sortKey="Tihon, Francois" sort="Tihon, Francois" uniqKey="Tihon F" first="François" last="Tihon">François Tihon</name><name sortKey="Verheyden, Ilse" sort="Verheyden, Ilse" uniqKey="Verheyden I" first="Ilse" last="Verheyden">Ilse Verheyden</name><name sortKey="Victor, Jan" sort="Victor, Jan" uniqKey="Victor J" first="Jan" last="Victor">Jan Victor</name></noCountry><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Dhont, Patrick A" sort="Dhont, Patrick A" uniqKey="Dhont P" first="Patrick A" last="Dhont">Patrick A. Dhont</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeBelgiqueV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000056 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000056 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeBelgiqueV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22678831
|texte= Acceptability of Intanza® 15 μg intradermal influenza vaccine in Belgium during the 2010-2011 influenza season.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22678831" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeBelgiqueV4
| This area was generated with Dilib version V0.6.35. |  |